🏛️ Verified NIH Record • Updated 2026-05-18
Non-Invasive Quantification of Liver Health in NASH (N-QUAN) (NCT04054310)
Non-Invasive Quantification of Liver Health in NASH (N-QUAN): A Prospective Diagnostic Accuracy Study
🟢 Recruiting Observational / Diagnostic 📋 Clinical Research Protocol Sponsor: Perspectum
🩺 Plain-English Summary (8th-Grade Level)
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
Who can join: Review the eligibility criteria below.
Location: Arizona Liver Health — Chandler, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
- Liver Multi Scan (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Arizona Liver Health — Chandler, Arizona
- RUSH University Medical Center — Chicago, Illinois
- Indiana University Health — Indianapolis, Indiana
- Icahn School of Medicine at Mount Sinai — New York, New York
- Liver Center of Texas — Dallas, Texas
- University of Virginia — Charlottesville, Virginia
- Virginia Common wealth University — Richmond, Virginia
📞 Contact the Study Coordinator
Phone: 01865655343
Email: cayden.beyer@perspectum.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in NASH - Nonalcoholic Steatohepatitis
- Statins for the Treatment of NASH — Rochester, Minnesota
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) — Birmingham, Alabama
- Estrogen Administration for the Treatment of NASH in Postmenopausal Women — Boston, Massachusetts
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis — Birmingham, Alabama
- Novel MRE Technique to Assess a Risk Factor for Liver Cancer — Stanford, California
- Hepatic Energy Fluxes in NASH and NAS Patients — Minneapolis, Minnesota
Explore by condition: All NASH - Nonalcoholic Steatohepatitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.